Spots Global Cancer Trial Database for oligometastatic prostate cancer
Every month we try and update this database with for oligometastatic prostate cancer cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study of SBRT as Treatment for Oligometastases in Prostate Cancer | NCT02192788 | Oligometastatic... | Stereotactic Bo... | 18 Years - | Grupo de Investigación Clínica en Oncología Radioterapia | |
| Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer | NCT01087580 | PROSTATE CANCER | Docetaxel and P... Docetaxel and P... Radiation Thera... | 18 Years - | Northwestern University | |
| [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer | NCT06229366 | Prostate Cancer Metastatic Cast... Biochemically R... | [Ac-225]-PSMA-6... [Ac-225]-PSMA-6... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| 5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT) | NCT04610372 | Oligometastatic... | Hypofractionate... High dose rate ... Permanent seed ... Stereotactic bo... | 18 Years - | British Columbia Cancer Agency | |
| Docetaxel + Prednisone With or Without Radiation for Castrate Resistant Prostate Cancer | NCT01087580 | PROSTATE CANCER | Docetaxel and P... Docetaxel and P... Radiation Thera... | 18 Years - | Northwestern University | |
| Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer | NCT04599686 | Treatment | ADT SBRT | 18 Years - 99 Years | Changhai Hospital | |
| [Ac-225]-PSMA-62 Trial in Biochemically Recurrent and Metastatic Castration Resistant Prostate Cancer | NCT06229366 | Prostate Cancer Metastatic Cast... Biochemically R... | [Ac-225]-PSMA-6... [Ac-225]-PSMA-6... | 18 Years - | POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company | |
| Prostate Cancer Biobank | NCT04024475 | Prostatic Neopl... | Observation | 18 Years - 70 Years | Swiss Group for Clinical Cancer Research | |
| Prostate Cancer Biobank | NCT04024475 | Prostatic Neopl... | Observation | 18 Years - 70 Years | Swiss Group for Clinical Cancer Research | |
| Prostate Oligometastatic Cancer Management Driven by Disease Biology et/or Immunoactivity (PROMETEO) | NCT06060652 | Oligometastatic... | 18 Years - | Centro di Riferimento Oncologico - Aviano | ||
| Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer | NCT05915442 | Oligometastatic... | Quemliclustat Etrumadenant Zimberelimab Stereotactic Bo... | 18 Years - 99 Years | Columbia University | |
| Radiotherapy for Oligometastatic Prostate Cancer | NCT01859221 | Oligometastatic... | Stereotactic ra... | 18 Years - | University of Florida | |
| Stereotactic Body Radiotherapy (SBRT) for Oligometastatic Prostate Cancer | NCT04599686 | Treatment | ADT SBRT | 18 Years - 99 Years | Changhai Hospital | |
| Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO) | NCT06387056 | Locally Advance... Oligometastatic... | Rezvilutamide Goserelin Micro... Docetaxel Pamiparib Cisplatin Tislelizumab | 18 Years - | The First Affiliated Hospital of Xiamen University | |
| The Efficacy and Safety of Prostatectomy for Castration-Naive Oligometastatic Prostate Cancer | NCT04992026 | Prostatectomy Oligometastatic... Abiraterone | robot assisted ... 1.Abiraterone A... Prednisone Acet... Luteinizing Hor... | 40 Years - 75 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative Radiotherapy | NCT05560659 | Oligometastatic... | 177Lu-PSMA | 18 Years - | Peter MacCallum Cancer Centre, Australia |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
